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Abstract
© 2016, Springer Science+Business Media New York.Though normally bone regenerates well,
non-union, delayed union, or defective bone formation can occur. Since impaired healing is
often caused by local trophic disorders, standard fracture management is often ineffective.
Gene therapy is a promising field for bone engineering. We have created a recombinant plasmid
construct  encoding  the  genes  for  pro-angiogenic  vascular  endothelial  growth  factor  165A
(VEGF165A)  and  pro-osteogenic  bone  morphogenetic  protein  2  (BMP2)  with  kanamycin
resistance (pBudKan-VEGF165A-BMP2). This plasmid has the potential for use in treatment of
trauma and skeletal system disorders, especially in cases of low trophicity.
http://dx.doi.org/10.1007/s12668-016-0300-3
Keywords
Angiogenesis, Bone morphogenetic protein 2 (BMP2), Osteogenesis, Plasmid, Vascular
endothelial growth factor (VEGF165)
References
[1] Kayal, R. A., Tsatsas, D., Bauer, M. A., Allen, B., Al-Sebaei, M. O., Kakar, S., et al. (2014). Diminished bone
formation during diabetic fracture healing is related to the premature resorption of cartilage associated with
increased osteoclast activity. Journal of Bone and Mineral Research, 22(4), 560–568.
[2] Morshed,  S.  (2014).  Current  options  for  determining  fracture  union.  Advances  in  Medicine.
doi:10.1155/2014/708574.
[3] Perlman, M. H., & Thordarson, D. B. (1999). Ankle fusion in a high risk population: an assessment of nonunion
risk factors. Foot and Ankle International, 20(8), 491–496.
[4] Murphey, M. D., Foreman, K. L., Klassen-Fischer, M. K., Fox, M. G., Chung, E. M., Kransdorf, M. J. (2014). From
the radiologic pathology archives imaging of osteonecrosis: radiologic-pathologic correlation. Radiographics,
34(4), 1003–1028.
[5] Reddi,  A. H. (1994). Bone and cartilage differentiation. Current Opinion in Genetics and Development, 4,
737–744.
[6] Lo, K. W.-H., Ulery, B. D., Ashe, K. M., Laurencin, C. T. (2016). Studies of bone morphogenetic protein based
surgical repair. Advanced Drug Delivery Reviews, 64(12), 1277–1291.
[7] Xiao, C., Zhou, H., Liu, G., Zhang, P., Fu, Y., Gu, P., et al. (2011). Bone marrow stromal cells with a combined
expression of BMP-2 and VEGF-165 enhanced bone regeneration. Biomedical Materials, 6(1), 015013.
[8] Bao, P.,  Kodra,  A.,  Tomic-Canic,  M.,  Golinko,  M. S.,  Ehrlich,  H.  P.,  Brem, H. (2009).  The role of  vascular
endothelial growth factor in wound healing. The Journal of Surgical Research, 153(2), 347–358.
[9] Kanczler, J. M., & Oreffo, R. O. (2008). Osteogenesis and angiogenesis: the potential for engineering bone.
European Cells & Materials, 15, 100–114.
[10] Masgutov RF, Bozo IY, Rizvanov AA, Isaev AA, Bogov AA, Bogov AA J, Deev RV, Salafutdinov II, Plaksa IL (2014)
Codon-optimized recombinant plasmid, method of peripheral  nerve regeneration, method of treatment of
human injured nerve. Russian Federation patent RU 2 558 294 C1.
[11] Declercq, H., Van den Vreken, N., De Maeyer, E., Verbeeck, R., Schacht, E., De Ridder, L.,  et al.  (2004).
Isolation, proliferation and differentiation of osteoblastic cells to study cell/biomaterial interactions: comparison
of different isolation techniques and source. Biomaterials, 25(5), 757–768.
[12] Katina, M. N., Gaifullina, R. F., Hayatova, Z. G., Emene, C. C., Rizvanov, A. A. (2012). Isolation, culture and
differentiation of rat (Rattus norvegicus) and hamster (Mesocricetus auratus) adipose derived multipotent stem
cells. Genes and Cells, 7(3), 82–87.
[13] Chen, S. M., Ward, S. I., Olutoye, O. O., Diegelmann, R. F., Kelman Cohen, I. (1997). Ability of chronic wound
fluids to degrade peptide growth factors is associated with increased levels of elastase activity and diminished
levels of proteinase inhibitors. Wound Repair and Regeneration, 5(1), 23–32.
[14] Chira, S., Jackson, C. S., Oprea, I., et al. (2015). Progresses towards safe and efficient gene therapy vectors.
Oncotarget, 6(31), 30675–30703.
[15] Kempen, D. H., Lu, L., Heijink, A., Hefferan, T. E., Creemers, L. B., Maran, A., et al. (2009). Effect of local
sequential  VEGF and BMP-2 delivery  on ectopic  and orthotopic  bone regeneration.  Biomaterials,  30(14),
2816–2825.
[16] Peng, H., Usas, A., Olshanski, A., Ho, A. M., Gearhart, B., Cooper, G. M., et al. (2005). VEGF improves, whereas
sFlt1 inhibits, BMP2-induced bone formation and bone healing through modulation of angiogenesis. Journal of
Bone and Mineral Research, 20(11), 2017–2027.
[17] Zelzer,  E.,  & Olsen,  B.  R.  (2005).  Multiple roles of  vascular  endothelial  growth factor  (VEGF) in  skeletal
development, growth, and repair. Current Topics in Developmental Biology, 65, 169–187.
[18] Seamon, J., Wang, X., Cui, F., et al. (2013). Adenoviral delivery of the genes to rat mesenchymal stem cells
potentiates osteogenesis. Bone Marrow Research. doi:10.1155/2013/737580.
[19] Lin, Z., Wang, J.-S., Lin, L., et al. (2014). Effects of BMP2 and VEGF165 on the osteogenic differentiation of rat
bone marrow-derived mesenchymal stem cells. Experimental and Therapeutic Medicine, 7(3), 625–629.
[20] Stoll, S. M., & Calos, M. P. (2002). Extrachromosomal plasmid vectors for gene therapy. Current Opinion in
Molecular Therapeutics, 4, 299–305.
[21] Herweijer, H., Zhang, G., Subbotin, V. M., Budker, V., Williams, P., Wolff, J. A. (2001). Time course of gene
expression after plasmid DNA gene transfer to the liver. The Journal of Gene Medicine, 3(3), 280–291.
[22] Herweijer, H., & Wolff, J. A. (2003). Progress and prospects: naked DNA gene transfer and therapy. Gene
Therapy, 10(6), 453–458.
[23] Morrissey, D., Collins, S. A., Rajenderan, S., Casey, G., O’Sullivan, G. C., Tangney, M. (2013). Plasmid transgene
expression in vivo: promoter and tissue variables (pp. 35–47). Rijeka: InTech.
[24] Ghodadra, N., & Singh, K. (2008). Recombinant human bone morphogenetic protein-2 in the treatment of bone
fractures. Biologics: Targets and Therapy, 2(3), 345–354.
[25] Deev, R. V., Drobyshev, A. Y., Bozo, I. Y., Isaev, A. A. (2015). Ordinary and activated bone grafts: applied
classification and the main features. BioMed Research International. doi:10.1155/2015/365050.
[26] Huber, P. E., & Pfisterer, P. (2000). In vitro and in vivo transfection of plasmid DNA in the Dunning prostate
tumor R3327-AT1 is enhanced by focused ultrasound. Gene Therapy, 7(17), 1516–1525.
[27] DiFranco, M., Quinonez, M., Capote, J., Vergara, J. (2009). DNA transfection of mammalian skeletal muscles
using in vivo electroporation. Journal of Visualized Experiments, 32, 1520.
